← Back to headlines
Edgewise Therapeutics Price Target Raised to $59 on Positive HCM Trial Data
Edgewise Therapeutics, Inc. (EWTX) has had its price target raised to $59 by analysts following positive data from its HCM (Hypertrophic Cardiomyopathy) trial.
25 Jun, 12:41 — 25 Jun, 12:41
Sources
Showing 1 of 1 sources
Related Stories
Japan Household Spending Falls for Eighth Consecutive Month Amid Rising Prices
18m ago
South Korea Prepares Military Deployment Near Strait of Hormuz Amid Regional Tensions
27m ago
US Probes Fatal Strike on Iranian Wedding Linked to American Munitions
31m ago
Skepticism Mounts Over Reported $100 Billion US-Venezuela Oil Deal
46m ago